Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:12
06/21/21
06/21
09:12
06/21/21
09:12
RAVN

Raven

$38.58 /

-2.18 (-5.35%)

, CNHI

CNH Industrial

$16.20 /

-0.57 (-3.40%)

, MNOV

MediciNova

$3.77 /

-0.04 (-1.05%)

, ENOB

Enochian Biosciences

$5.78 /

-0.13 (-2.20%)

, TRCH

Torchlight Energy Resources

$6.26 /

+0.875 (+16.25%)

, ALLO

Allogene Therapeutics

$24.47 /

-0.21 (-0.85%)

, TBPH

Theravance Biopharma

$17.50 /

-0.09 (-0.51%)

, IMMP

Immutep

$4.70 /

+ (+0.00%)

, RIOT

Riot Blockchain

$32.18 /

-2.07 (-6.04%)

, MARA

Marathon Digital

$28.92 /

-1.09 (-3.63%)

, COIN

Coinbase

$229.47 /

-0.87 (-0.38%)

Check out this morning's…

ShowHide Related Items >><<
TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

05/18/21 Lake Street
Raven price target raised to $55 from $50
03/19/21 Lake Street
Raven initiated with a Buy at Lake Street
CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

05/12/21 Evercore ISI
CNH Industrial price target raised to $25 from $18 at Evercore ISI
05/07/21 BofA
CNH Industrial added to US 1 List at BofA
04/23/21 AlphaValue
CNH Industrial upgraded to Add from Sell at AlphaValue
04/13/21 Deutsche Bank
CNH Industrial price target raised to $21 from $18 at Deutsche Bank
MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

03/10/21
Fly Intel: Top five analyst initiations
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
03/10/21 Maxim
MediciNova initiated with a Buy at Maxim
ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

03/09/21 SVB Leerink
Theravance Biopharma sum-of-the-parts may be worth $78/share, says SVB Leerink
02/24/21 SVB Leerink
Theravance Biopharma price target raised to $41 from $35 at SVB Leerink
11/23/20 Evercore ISI
Theravance Biopharma resumed with an Outperform at Evercore ISI
10/14/20 Morgan Stanley
Morgan Stanley upgrades Theravance Biopharma to Overweight following pullback
IMMP Immutep
$4.70 /

+ (+0.00%)

06/10/21 Alliance Global Partners
Immutep price target raised to $9 from $6 at Alliance Global Partners
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
01/26/21 Alliance Global Partners
Immutep price target raised to $6 from $5 at Alliance Global Partners
12/14/20 Maxim
Maxim doubled Immutep price target after breast cancer update
RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

06/21/21 Compass Point
Compass Point starts Riot Blockchain at Buy after 'transformational' deal
06/21/21 Compass Point
Riot Blockchain initiated with a Buy at Compass Point
06/01/21 B. Riley
Riot Blockchain deal closing 'major positive' for shares, says B. Riley
06/01/21 H.C. Wainwright
Riot Blockchain price target raised to $40 from $30 at H.C. Wainwright
MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

06/21/21 Compass Point
Compass sees Marathon Digital becoming largest bitcoin miner, starts at Buy
06/21/21 Compass Point
Marathon Digital initiated with a Buy at Compass Point
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 B. Riley
Marathon Digital initiated with a Buy, $47 target at B. Riley
COIN Coinbase
$229.47 /

-0.87 (-0.38%)

06/16/21
Fly Intel: Top five analyst initiations
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/16/21 Canaccord
Coinbase initiated with a Buy at Canaccord
06/08/21 Raymond James
Raymond James starts Coinbase at Underperform, sees fee compression coming
TBPH Theravance Biopharma
$17.50 /

-0.09 (-0.51%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

CNHI CNH Industrial
$16.20 /

-0.57 (-3.40%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

  • 14
    Apr
  • 08
    Feb
  • 24
    Jul
TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

RAVN Raven
$38.58 /

-2.18 (-5.35%)

MNOV MediciNova
$3.77 /

-0.04 (-1.05%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

ENOB Enochian Biosciences
$5.78 /

-0.13 (-2.20%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

TRCH Torchlight Energy Resources
$6.26 /

+0.875 (+16.25%)

RIOT Riot Blockchain
$32.18 /

-2.07 (-6.04%)

MARA Marathon Digital
$28.92 /

-1.09 (-3.63%)

IMMP Immutep
$4.70 /

+ (+0.00%)

COIN Coinbase
$229.47 /

-0.87 (-0.38%)

Initiation
Allogene Therapeutics assumed with a Buy at Jefferies » 07:51
06/21/21
06/21
07:51
06/21/21
07:51
ALLO

Allogene Therapeutics

$24.47 /

-0.21 (-0.85%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee assumed coverage of Allogene Therapeutics with a Buy rating and $53 price target, telling investors that he views the recent pullback in the shares as an attractive buying opportunity. Data presented at ASCO "looked good" and he is looking forward to potentially "strong data" updates at ASH 2021 on CD19 and on BCMA, Yee tells investors. He additionally notes that Allogene will be in a pivotal study in diffuse large B-cell lymphoma, or DLBCL, by year end, which Yee said is "already far ahead of others."

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

Hot Stocks
Allogene Overland Biopharm appoints Shuyuan Yao as CEO » 07:05
06/21/21
06/21
07:05
06/21/21
07:05
ALLO

Allogene Therapeutics

$24.47 /

-0.21 (-0.85%)

Allogene Overland…

Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer. Dr. Yao brings 15 years of scientific and management experience in advanced cell and gene therapy development, manufacturing and commercialization to lead Allogene Overland in its mission to bring innovative AlloCAR therapies to patients in China and other Asian Pacific markets.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

ALLO Allogene Therapeutics
$24.47 /

-0.21 (-0.85%)

Over a week ago
Hot Stocks
Allogene Therapeutics presents Phase 1 data on ALLO-501, ALLO-501A » 09:20
06/04/21
06/04
09:20
06/04/21
09:20
ALLO

Allogene Therapeutics

$24.06 /

-0.71 (-2.87%)

Allogene Therapeutics…

Allogene Therapeutics presented data from multiple studies across lead anti-CD19 AlloCAR T therapy programs in two poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting being held virtually June 4 - 8, 2021. The ASCO presentations include data from Phase 1 ALPHA and ALPHA2 trials in relapsed/refractory non-Hodgkin lymphoma, developed in collaboration with Servier, and presented in the Developmental Therapeutics - Immunotherapy session by Frederick L. Locke, M.D., Co-Leader, Moffitt Immuno-Oncology Program, Vice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center. Safety, pharmacokinetic and pharmacodynamic data from ALLO-647, a component of the Company's differentiated lymphodepletion regimen, will be presented in the same session by Michael Tees, M.D., M.P.H., Associate Member Physician, Colorado Blood Cancer Institute, Sarah Cannon Research Institute. Due to the virtual nature of the meeting, the ASCO presentations were finalized in advance of Allogene's CD19 Forum on May 19, 2021. As such, data presented at the CD19 Forum, accessible via this link and included below, is more comprehensive and reflects information collected as of May 12, 2021 from the ALPHA and ALPHA2 studies. The Company intends to initiate a Phase 2 trial with ALLO-501A, pending regulatory feedback, by the end of 2021. The next clinical update on the CD19 program is planned for Q4 2021. Data presented from the ALPHA trial supports the ability of a single administration of ALLO-501 to generate deep and durable responses at a rate that is similar to approved autologous CAR T therapies. As of the April 19, 2021 data cutoff, 42 patients were enrolled and 41 received ALLO-501, including nine who had previously received autologous CAR T treatment. The one patient not treated was enrolled but removed from the study prior to lymphodepletion due to lymphoma related obstructive kidney disease. In the trial, 98% of patients received ALLO-501 and the median and mean time from enrollment to the start of therapy was five days. Responses were observed across all cell doses and tumor histologies and follicular lymphoma. The percent of these patients remaining in complete response at six months following a single infusion was 29%, with 36% in LBCL and 24% in FL. An additional four FL patients in response have yet to reach the six month timepoint. As of May 12, 2021, three LBCL patients remain in CR and eight FL patients remain in CR, with the longest ongoing CRs at 15 months. Redosing led to clinical responses, with an overall Treatment Failure Free Survival for autologous naive patients of 64% and 61% at six months for FL and LBCL, respectively. ALLO-647 was used in lymphodepletion with fludarabine/cyclophosphamide at doses ranging from 39mg to 90mg. No dose limiting toxicities or graft-vs-host disease were observed and one case of Grade 3 Immune Effector Cell-Associated Neurotoxicity Syndrome was reported. Cytokine release syndrome occurred in 27% of patients, was limited to Grade 1 or 2, and was manageable with standard protocols. Infection rates were similar to those observed in autologous CAR T trials. During this study, there were five treatment-emergent deaths in the absence of disease progression, one each from pneumonia, arrythmia, and stroke, and two instances of COVID-19 acquired in the community setting. Three of these patients were in ongoing CR at the time of death. ALLO-501A is a next generation anti-CD19 AlloCAR T candidate intended for a pivotal trial and is engineered without the rituximab recognition domains included in ALLO-501. This trial is only enrolling patients with relapsed/refractory LBCL. Following promising efficacy data from patients treated at dose level 2 patient enrollment in ALPHA2 focused on exploration of a consolidated dosing strategy that enabled patients who did not progress following an initial dose of ALLO-501A to receive a second, scheduled dose of cells. In consolidation dosing, 60mg ALLO-647 was provided with Flu/Cy for lymphodepletion before the first cell administration at DL2, and 30mg ALLO-647 with no Flu/Cy was provided for lymphodepletion before the second cell infusion at DL2 to patients with selective hematologic criteria. As of the April 19, 2021 data cutoff, 13 patients were enrolled and 12 patients were treated with ALLO-501A. One patient was treated with ALLO-647 but not ALLO-501A and deemed unable to proceed due to disease progression. Nine patients treated at the targeted 120M cell dose were evaluable for efficacy were CAR T naive, except for one who received prior autologous CAR T and previously had a 16-week CR followed by relapse. Data from these nine patients demonstrate efficacy and safety for ALLO-501A consistent with that observed for ALLO-501 in the ALPHA trial. As of May 12, 2021, all of the CRs remain ongoing, with a median follow-up of 2.3 months. Of the eight patients treated in the consolidation cohorts across both ALPHA studies, the ORR was 75% and CR rate was 63%, with four patients converting from a partial response at day 28 to a CR at day 56. No dose limiting toxicities, GvHD or ICANS were observed in ALPHA2.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$24.06 /

-0.71 (-2.87%)

ALLO Allogene Therapeutics
$24.06 /

-0.71 (-2.87%)

05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
ALLO Allogene Therapeutics
$24.06 /

-0.71 (-2.87%)

ALLO Allogene Therapeutics
$24.06 /

-0.71 (-2.87%)

Over a month ago
Conference/Events
Allogene Therapeutics participates in a conference call with JPMorgan » 10:21
05/21/21
05/21
10:21
05/21/21
10:21
ALLO

Allogene Therapeutics

$26.26 /

-0.6 (-2.23%)

Conference call with CEO…

Conference call with CEO Chang, Chief Medical Officer Amado, CFO Schmidt and Chief Communications Officer Cassiano will be held on May 21 at 11 am. Webcast Link

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$26.26 /

-0.6 (-2.23%)

ALLO Allogene Therapeutics
$26.26 /

-0.6 (-2.23%)

05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
ALLO Allogene Therapeutics
$26.26 /

-0.6 (-2.23%)

  • 02
    Jun
ALLO Allogene Therapeutics
$26.26 /

-0.6 (-2.23%)

Recommendations
Allogene update exceeds expectation 'on all fronts,' says Jefferies » 09:03
05/20/21
05/20
09:03
05/20/21
09:03
ALLO

Allogene Therapeutics

$28.42 /

-1.5 (-5.01%)

Jefferies analyst Kelly…

Jefferies analyst Kelly Shi said Allogene's ALLO-501A update tied to the ASCO meeting exceeded her expectations on "all fronts" and "checks all the boxes for a compelling profile" compared to autologous peers. The six-month complete response rate reached 36%, with the longest ongoing CR at 15 months upon a single dose of ALLO501 in DLBCL patients, noted Shi. The analyst, wo think ALLO501(A) is "poised to be disruptive" to the non-Hodgkin lymphoma treatment paradigm and cell therapy field, has a Buy rating and $53 price target on Allogene shares.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/14/21 B. Riley
B. Riley starts Allogene Therapeutics with Buy, $52 price target
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

  • 02
    Jun
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

Recommendations
Allogene data 'better than they appear on the surface,' says Stifel » 08:33
05/20/21
05/20
08:33
05/20/21
08:33
ALLO

Allogene Therapeutics

$28.42 /

-1.5 (-5.01%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett said the ASCO data Allogene presented are "good" and "better than they appear on the surface," as well as better than what after-hours trading last night implied. He had been looking for a LBCL six-month complete response rate in "the low 30% range" and thinks the "durable 6-month" CR rate is probably closer to 33%, not 25%, "depending on how one considers a patient who died while in remission just after the 6-month time-point," Burnett tells investors. The analyst, who argues that "25% is an overly pessimistic estimate of the true durable CR-rate," reiterates his Buy rating and $44 price target on Allogene shares following the ASCO update.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/14/21 B. Riley
B. Riley starts Allogene Therapeutics with Buy, $52 price target
05/13/21 B. Riley
Allogene Therapeutics initiated with a Buy at B. Riley
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

  • 02
    Jun
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

Upgrade
Allogene Therapeutics upgraded to Buy from Hold at Truist » 07:11
05/20/21
05/20
07:11
05/20/21
07:11
ALLO

Allogene Therapeutics

$28.42 /

-1.5 (-5.01%)

Truist analyst Asthika…

Truist analyst Asthika Goonewardene upgraded Allogene Therapeutics to Buy from Hold with a price target of $41, up from $34. The company's ASCO data presentation previewed yesterday is "encouraging", with Allogene beginning to "hold a candle to its autologous cousins", the analyst tells investors in a research note. Goonewardene adds that the exploratory re-dosing and consolidation strategy hints at potential to deepen responses, and he expects Allogene to make this core to its treatment strategy.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

05/20/21 Truist
Allogene Therapeutics upgraded to Buy from Hold at Truist
05/14/21 B. Riley
B. Riley starts Allogene Therapeutics with Buy, $52 price target
05/13/21 B. Riley
Allogene Therapeutics initiated with a Buy at B. Riley
03/01/21 H.C. Wainwright
Allogene Therapeutics price target raised to $43 from $40 at H.C. Wainwright
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

  • 02
    Jun
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

Upgrade
Allogene Therapeutics upgraded to Buy from Hold at Truist » 06:53
05/20/21
05/20
06:53
05/20/21
06:53
ALLO

Allogene Therapeutics

$28.42 /

-1.5 (-5.01%)

Truist analyst Asthika…

Truist analyst Asthika Goonewardene upgraded Allogene Therapeutics to Buy from Hold with a price target of $41, up from $34.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

05/14/21 B. Riley
B. Riley starts Allogene Therapeutics with Buy, $52 price target
05/13/21 B. Riley
Allogene Therapeutics initiated with a Buy at B. Riley
03/01/21 H.C. Wainwright
Allogene Therapeutics price target raised to $43 from $40 at H.C. Wainwright
01/26/21 Stifel
Allogene Therapeutics upgraded to Buy from Hold at Stifel
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

  • 02
    Jun
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

On The Fly
Fly Intel: After-Hours Movers » 19:01
05/19/21
05/19
19:01
05/19/21
19:01
CPRT

Copart

$121.01 /

-0.22 (-0.18%)

, SNPS

Synopsys

$237.14 /

+1.85 (+0.79%)

, ONCT

Oncternal Therapeutics

$5.56 /

-0.23 (-3.97%)

, ADAP

Adaptimmune

$4.90 /

-0.22 (-4.30%)

, SNSE

Sensei Biotherapeutics

$9.67 /

+0.47 (+5.11%)

, ALLO

Allogene Therapeutics

$28.42 /

-1.5 (-5.01%)

, AVEO

Aveo Pharmaceuticals

$6.84 /

-0.35 (-4.87%)

, SCVL

Shoe Carnival

$62.39 /

-1.36 (-2.13%)

, CSCO

Cisco

$52.44 /

-0.48 (-0.91%)

, SBLK

Star Bulk Carriers

$22.51 /

+0.45 (+2.04%)

, LB

L Brands

$67.31 /

-2.18 (-3.14%)

, KEYS

Keysight Technologies

$138.11 /

-0.64 (-0.46%)

, BDTX

Black Diamond Therapeutics

$22.21 /

-1.175 (-5.02%)

Check out this evening's…

ShowHide Related Items >><<
SNSE Sensei Biotherapeutics
$9.67 /

+0.47 (+5.11%)

SNPS Synopsys
$237.14 /

+1.85 (+0.79%)

SCVL Shoe Carnival
$62.39 /

-1.36 (-2.13%)

SBLK Star Bulk Carriers
$22.51 /

+0.45 (+2.04%)

ONCT Oncternal Therapeutics
$5.56 /

-0.23 (-3.97%)

LB L Brands
$67.31 /

-2.18 (-3.14%)

KEYS Keysight Technologies
$138.11 /

-0.64 (-0.46%)

CSCO Cisco
$52.44 /

-0.48 (-0.91%)

CPRT Copart
$121.01 /

-0.22 (-0.18%)

BDTX Black Diamond Therapeutics
$22.21 /

-1.175 (-5.02%)

AVEO Aveo Pharmaceuticals
$6.84 /

-0.35 (-4.87%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ADAP Adaptimmune
$4.90 /

-0.22 (-4.30%)

CPRT Copart
$121.01 /

-0.22 (-0.18%)

02/12/21 Stephens
Copart upgraded to Overweight on global salvage outlook at Stephens
02/12/21 Stephens
Copart upgraded to Overweight from Equal Weight at Stephens
02/05/21 Northcoast
Copart upgraded to Buy from Neutral at Northcoast
12/07/20
Fly Intel: Top five analyst initiations
SNPS Synopsys
$237.14 /

+1.85 (+0.79%)

02/18/21 DA Davidson
Synopsys price target raised to $335 from $285 at DA Davidson
02/18/21 Needham
Synopsys price target raised to $310 from $275 at Needham
02/18/21 Credit Suisse
Synopsys price target raised to $300 from $265 at Credit Suisse
02/18/21 KeyBanc
Synopsys price target raised to $320 from $315 at KeyBanc
ONCT Oncternal Therapeutics
$5.56 /

-0.23 (-3.97%)

04/06/21 Oppenheimer
Opco starts Oncternal at Outperform on 'compelling' lead asset data
04/06/21 Oppenheimer
Oncternal Therapeutics initiated with an Outperform at Oppenheimer
03/30/21
Fly Intel: Top five analyst initiations
03/30/21 Brookline
Oncternal Therapeutics initiated with a Buy at Brookline
ADAP Adaptimmune
$4.90 /

-0.22 (-4.30%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
SNSE Sensei Biotherapeutics
$9.67 /

+0.47 (+5.11%)

03/02/21 Berenberg
Sensei Biotherapeutics initiated with a Buy at Berenberg
03/01/21
Fly Intel: Top five analyst initiations
03/01/21 Oppenheimer
Sensei Biotherapeutics initiated with an Outperform at Oppenheimer
03/01/21 Citi
Sensei Biotherapeutics initiated with a Buy at Citi
ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

05/14/21 B. Riley
B. Riley starts Allogene Therapeutics with Buy, $52 price target
05/13/21 B. Riley
Allogene Therapeutics initiated with a Buy at B. Riley
03/01/21 H.C. Wainwright
Allogene Therapeutics price target raised to $43 from $40 at H.C. Wainwright
01/26/21 Stifel
Allogene Therapeutics upgraded to Buy from Hold at Stifel
AVEO Aveo Pharmaceuticals
$6.84 /

-0.35 (-4.87%)

03/11/21 Baird
Aveo Pharmaceuticals Fotivda early approval a positive, says Baird
01/29/21 Baird
Aveo Pharmaceuticals assumed at Outperform at Baird
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Stifel
Aveo Pharmaceuticals initiated with a Buy at Stifel
SCVL Shoe Carnival
$62.39 /

-1.36 (-2.13%)

05/17/21 Pivotal Research
Shoe Carnival price target raised to $74 from $68 at Pivotal Research
02/22/21 Williams Capital
Shoe Carnival initiated with a Buy at Williams Trading
12/08/20 Jefferies
Deckers Brands price target raised to $346 from $315 at Jefferies
11/19/20 Susquehanna
Shoe Carnival price target raised to $47 from $40 at Susquehanna
CSCO Cisco
$52.44 /

-0.48 (-0.91%)

05/14/21 Raymond James
Cisco price target raised to $55 from $50 at Raymond James
05/13/21 MKM Partners
Cisco initiated with a Buy at MKM Partners
04/23/21 KeyBanc
Cisco resumed with a Sector Weight at KeyBanc
04/20/21
Fly Intel: Top five analyst initiations
SBLK Star Bulk Carriers
$22.51 /

+0.45 (+2.04%)

05/18/21 Deutsche Bank
Star Bulk Carriers price target raised to $40 from $18 at Deutsche Bank
03/11/21 Deutsche Bank
Star Bulk Carriers price target raised to $18 from $15 at Deutsche Bank
01/29/21 Jefferies
Star Bulk Carriers price target raised to $13 from $10 at Jefferies
12/01/20 Pareto
Star Bulk Carriers downgraded to Hold from Buy at Pareto
LB L Brands
$67.31 /

-2.18 (-3.14%)

05/13/21 Barclays
L Brands price target raised to $82 from $66 at Barclays
05/12/21 RBC Capital
L Brands price target raised to $70 from $65 at RBC Capital
05/12/21 Deutsche Bank
L Brands price target raised to $87 from $80 at Deutsche Bank
05/12/21 Citi
L Brands price target raised to $70 from $62 at Citi
KEYS Keysight Technologies
$138.11 /

-0.64 (-0.46%)

02/05/21 JPMorgan
Keysight Technologies price target raised to $165 from $135 at JPMorgan
01/25/21 Deutsche Bank
Keysight downgraded to Hold after rally at Deutsche Bank
01/25/21 Deutsche Bank
Keysight Technologies downgraded to Hold from Buy at Deutsche Bank
01/22/21 Citi
Keysight Technologies price target raised to $175 from $130 at Citi
BDTX Black Diamond Therapeutics
$22.21 /

-1.175 (-5.02%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
SNSE Sensei Biotherapeutics
$9.67 /

+0.47 (+5.11%)

SNPS Synopsys
$237.14 /

+1.85 (+0.79%)

SCVL Shoe Carnival
$62.39 /

-1.36 (-2.13%)

SBLK Star Bulk Carriers
$22.51 /

+0.45 (+2.04%)

ONCT Oncternal Therapeutics
$5.56 /

-0.23 (-3.97%)

LB L Brands
$67.31 /

-2.18 (-3.14%)

KEYS Keysight Technologies
$138.11 /

-0.64 (-0.46%)

CSCO Cisco
$52.44 /

-0.48 (-0.91%)

CPRT Copart
$121.01 /

-0.22 (-0.18%)

BDTX Black Diamond Therapeutics
$22.21 /

-1.175 (-5.02%)

AVEO Aveo Pharmaceuticals
$6.84 /

-0.35 (-4.87%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

ADAP Adaptimmune
$4.90 /

-0.22 (-4.30%)

  • 24
    Mar
  • 04
    Feb
  • 18
    Nov
  • 28
    Aug
  • 17
    Jun
  • 02
    Jun
  • 02
    Jun
LB L Brands
$67.31 /

-2.18 (-3.14%)

CSCO Cisco
$52.44 /

-0.48 (-0.91%)

SNSE Sensei Biotherapeutics
$9.67 /

+0.47 (+5.11%)

SNPS Synopsys
$237.14 /

+1.85 (+0.79%)

SCVL Shoe Carnival
$62.39 /

-1.36 (-2.13%)

SBLK Star Bulk Carriers
$22.51 /

+0.45 (+2.04%)

ONCT Oncternal Therapeutics
$5.56 /

-0.23 (-3.97%)

LB L Brands
$67.31 /

-2.18 (-3.14%)

CSCO Cisco
$52.44 /

-0.48 (-0.91%)

CPRT Copart
$121.01 /

-0.22 (-0.18%)

AVEO Aveo Pharmaceuticals
$6.84 /

-0.35 (-4.87%)

ALLO Allogene Therapeutics
$28.42 /

-1.5 (-5.01%)

SNPS Synopsys
$237.14 /

+1.85 (+0.79%)

ONCT Oncternal Therapeutics
$5.56 /

-0.23 (-3.97%)

LB L Brands
$67.31 /

-2.18 (-3.14%)

CSCO Cisco
$52.44 /

-0.48 (-0.91%)

BDTX Black Diamond Therapeutics
$22.21 /

-1.175 (-5.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.